alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.
Company profile
Ticker
ALNY
Exchange
Website
CEO
John Maraganore
Employees
Location
Fiscal year end
Industry (SIC)
Former names
ALNYLAM PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
Alnylam U.S., Inc. • Alnylam Securities Corporation • Sirna Therapeutics, Inc. • Alnylam Austria GmbH • Alnylam Brasil Farmaceutica Ltda. • Alnylam (Bermuda) Ltd. • Alnylam Canada ULC • Alnylam France SAS • Alnylam Europe AG • Alnylam Germany GmbH ...
IRS number
770602661
ALNY stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
1 Apr 24
DEFA14A
Additional proxy soliciting materials
1 Apr 24
DEF 14A
Definitive proxy
1 Apr 24
8-K
Departure of Directors or Certain Officers
4 Mar 24
10-K
2023 FY
Annual report
15 Feb 24
8-K
Results of Operations and Financial Condition
15 Feb 24
8-K
Departure of Directors or Certain Officers
19 Jan 24
8-K
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates
8 Jan 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Results of Operations and Financial Condition
2 Nov 23
Transcripts
ALNY
Earnings call transcript
2023 Q4
15 Feb 24
ALNY
Earnings call transcript
2023 Q3
2 Nov 23
ALNY
Earnings call transcript
2023 Q2
3 Aug 23
ALNY
Earnings call transcript
2023 Q1
4 May 23
ALNY
Earnings call transcript
2022 Q4
23 Feb 23
ALNY
Earnings call transcript
2022 Q3
27 Oct 22
ALNY
Earnings call transcript
2022 Q2
28 Jul 22
ALNY
Earnings call transcript
2022 Q1
28 Apr 22
ALNY
Earnings call transcript
2021 Q4
10 Feb 22
ALNY
Earnings call transcript
2021 Q3
28 Oct 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.04 bn | 1.04 bn | 1.04 bn | 1.04 bn | 1.04 bn | 1.04 bn |
Cash burn (monthly) | (no burn) | 3.35 mm | (no burn) | 36.64 mm | (no burn) | (no burn) |
Cash used (since last report) | n/a | 22.97 mm | n/a | 251.34 mm | n/a | n/a |
Cash remaining | n/a | 1.01 bn | n/a | 783.87 mm | n/a | n/a |
Runway (months of cash) | n/a | 302.3 | n/a | 21.4 | n/a | n/a |
Institutional ownership, Q3 2023
92.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 449 |
Opened positions | 54 |
Closed positions | 52 |
Increased positions | 155 |
Reduced positions | 157 |
13F shares | Current |
---|---|
Total value | 20.50 tn |
Total shares | 116.07 mm |
Total puts | 938.35 k |
Total calls | 883.80 k |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
Capital World Investors | 16.53 mm | $2.93 tn |
Vanguard | 11.66 mm | $2.06 tn |
FMR | 11.28 mm | $2.00 tn |
BLK Blackrock | 8.39 mm | $1.49 tn |
Baillie Gifford & Co | 8.16 mm | $1.45 tn |
Wellington Management | 6.43 mm | $1.14 tn |
T. Rowe Price | 3.93 mm | $694.39 bn |
Dodge & Cox | 3.75 mm | $663.62 bn |
T. Rowe Price Investment Management | 3.40 mm | $601.31 bn |
Capital International Investors | 3.10 mm | $548.62 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Mar 24 | Tolga Tanguler | Common Stock | Grant | Acquire A | No | No | 0 | 4,751 | 0.00 | 9,987 |
1 Mar 24 | Tolga Tanguler | Stock Option Common Stock | Grant | Acquire A | No | No | 152.61 | 9,279 | 1.42 mm | 9,279 |
1 Mar 24 | Pushkal Garg | Common Stock | Grant | Acquire A | No | No | 0 | 4,751 | 0.00 | 13,417 |
1 Mar 24 | Pushkal Garg | Stock Option Common Stock | Grant | Acquire A | No | No | 152.61 | 9,279 | 1.42 mm | 9,279 |
1 Mar 24 | Jeffrey V. Poulton | Common Stock | Grant | Acquire A | No | No | 0 | 7,741 | 0.00 | 27,219 |
1 Mar 24 | Jeffrey V. Poulton | Stock Option Common Stock | Grant | Acquire A | No | No | 152.61 | 15,118 | 2.31 mm | 15,118 |
1 Mar 24 | Yvonne Greenstreet | Common Stock | Grant | Acquire A | No | No | 0 | 23,754 | 0.00 | 71,882 |
1 Mar 24 | Yvonne Greenstreet | Stock Option Common Stock | Grant | Acquire A | No | No | 152.61 | 46,394 | 7.08 mm | 46,394 |
News
How Is The Market Feeling About Alnylam Pharmaceuticals?
19 Apr 24
10 Health Care Stocks With Whale Alerts In Today's Session
9 Apr 24
Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data
8 Apr 24
Reported Sunday, Alnylam Presents Results From The KARDIA-2 Phase 2 Study Of Zilebesiran Added To Standard Of Care Antihypertensives In Patients With Inadequately Controlled Hypertension
8 Apr 24
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
2 Apr 24
Press releases
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
7 Apr 24
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
20 Mar 24
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
13 Mar 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
11 Mar 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
7 Mar 24